Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vertex unveils promising VX-222/Incivek combo data in HCV

This article was originally published in Scrip

Executive Summary

Vertex Pharmaceuticals has no plans to rest on its laurels in the treatment of HCV. Hot on the heels of getting FDA approval for Incivek (telaprevir), the oral HCV protease inhibitor developed in collaboration with the Janssen Pharmaceutical company Tibotec Virco (, 23 May 2011), the company has unveiled interim Phase II data highlighting the potential of VX-222, its lead hepatitis C virus polymerase inhibitor, as part of a combination approach to treating genotype-1 hepatitis C.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts